LSTA

Lisata Therapeutics, Inc. (LSTA) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to enhance the delivery of anti-cancer drugs to solid tumors via the C-end rule active transport mechanism. The company operates as a single segment and is currently evaluating strategic alternatives, including potential mergers, acquisitions, or liquidation, following the termination of a proposed merger with Kuva Labs.

Key Financial Metrics

Note: Revenue was $0 for the current period. The company reported a net loss attributable to common stockholders of $2.9 million for the quarter and $7.4 million for the six months ended June 30, 2026.

Material Changes vs. Prior Period

• Revenue: Revenue decreased to $0 from $70,000 in the prior year quarter, as no license fees or milestones were recognized in the current period.
• Operating Expenses: Total operating expenses decreased by 19.2% ($0.9 million) in Q2 2026 compared to Q2 2025.
  • R&D Expenses: Decreased significantly by 74.1% ($1.7 million) due to the completion of the Phase 2a BOLSTER trial and reduced clinical department staffing.
  • G&A Expenses: Increased by 26.9% ($0.7 million) primarily driven by legal and consulting fees related to the proposed acquisition by Kuva Labs.
• Other Income: Increased to $1.1 million in Q2 2026 from $0.2 million in Q2 2025, largely due to a $1.0 million receipt from Kuva related to the Merger Agreement.
• Liquidity: Cash and cash equivalents declined by approximately $5.5 million during the six months ended June 30, 2026, driven by net cash used in operating activities of $5.7 million.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for twelve months following the issuance of these financial statements. Continued operations depend on raising additional funding or completing a strategic transaction.
• Merger Termination & Litigation: On July 24, 2026, the company terminated its Merger Agreement with Kuva Labs due to Kuva's failure to secure financing. Lisata is suing Kuva for a $2.0 million termination fee and additional damages. There is no assurance these funds will be recovered.
• Strategic Review: The Board is actively assessing strategic alternatives, including acquisition, merger, asset sales, or liquidation.
• Workforce Reduction: On August 3, 2026 (subsequent to the reporting period), the Board approved a 72% reduction in workforce to reduce operating expenses. Estimated costs are $1.2 million, partially offset by a $0.4 million reversal of accrued bonuses. This included the termination of the Executive Vice President of R&D and Chief Medical Officer.
• Clinical Pipeline: The company has delayed readiness activities for its planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC) to conserve cash. Investigator-sponsored studies in glioblastoma and other cancers are ongoing.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $10.4 million cash balance against the estimated $1.2 million severance costs and ongoing operational burn rate.
• Litigation Outcome: Assess the likelihood of recovering the $2.0 million termination fee and damages from Kuva Labs given the company's limited resources to fund litigation.
• Strategic Alternatives: Monitor progress on the strategic review process and the potential for a transaction versus liquidation.
• Capital Raising: Evaluate the feasibility of raising additional equity or debt capital given the "substantial doubt" going concern warning and recent workforce reduction.
• Regulatory Status: Confirm the status of the ASCEND trial data and the impact of the Qilu Pharmaceutical license termination on future commercialization rights in Greater China.